Advances in Pharmacological Research on Icaritin: A Comprehensive Review.

The American journal of Chinese medicine Pub Date : 2025-01-01 Epub Date: 2025-01-29 DOI:10.1142/S0192415X25500089
Ran Guo, Zhiping Yan, Rui Wang, Tongxuan Guo, Hao Li, Minyu Kong, Wenzhi Guo
{"title":"Advances in Pharmacological Research on Icaritin: A Comprehensive Review.","authors":"Ran Guo, Zhiping Yan, Rui Wang, Tongxuan Guo, Hao Li, Minyu Kong, Wenzhi Guo","doi":"10.1142/S0192415X25500089","DOIUrl":null,"url":null,"abstract":"<p><p><i>Epimedium</i> has been widely used in traditional Chinese medicine for several thousands of years. This plant is known for tonifying kidney Yang, strengthening muscles and bones, and dispelling wind and dampness. It is worth noting that icaritin, a prenylated flavonoid isolated from <i>Epimedium</i>, has received increasing attention in recent years due to its wide range of pharmacological activities. Icaritin exhibits significant therapeutic potential against various diseases, such as osteoporosis, tumors (hepatocellular carcinoma, stomach cancer, breast cancer, and glioblastoma), cerebral ischemia skin injury, thrombocytopenia, and systemic lupus erythematosus. We review the pharmacological activities of icaritin and its potential molecular mechanisms for the treatment of related diseases. The data suggest that icaritin can have the pharmacological effects of mediating Wnt/[Formula: see text]-catenin, IL-6/JAK2/STAT3, AMPK/mTOR, PTEN/AKT, MAPK, NF-[Formula: see text]B, and other signaling pathways. This paper also discusses the progress of clinical trials of icaritin. Icaritin was approved by the State Food and Drug Administration in January 2022 for the treatment of advanced HCC, and has various clinical drug prospects. Although it has some disadvantages, including poor solubility, and low bioavailability, icaritin is still a prospective candidate for the development of naturally derived drugs, especially in the treatment of tumors and inflammatory diseases. This review aims to update and deepen the understanding of icaritin, and provide a theoretical basis for its further study.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"179-203"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of Chinese medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/S0192415X25500089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Epimedium has been widely used in traditional Chinese medicine for several thousands of years. This plant is known for tonifying kidney Yang, strengthening muscles and bones, and dispelling wind and dampness. It is worth noting that icaritin, a prenylated flavonoid isolated from Epimedium, has received increasing attention in recent years due to its wide range of pharmacological activities. Icaritin exhibits significant therapeutic potential against various diseases, such as osteoporosis, tumors (hepatocellular carcinoma, stomach cancer, breast cancer, and glioblastoma), cerebral ischemia skin injury, thrombocytopenia, and systemic lupus erythematosus. We review the pharmacological activities of icaritin and its potential molecular mechanisms for the treatment of related diseases. The data suggest that icaritin can have the pharmacological effects of mediating Wnt/[Formula: see text]-catenin, IL-6/JAK2/STAT3, AMPK/mTOR, PTEN/AKT, MAPK, NF-[Formula: see text]B, and other signaling pathways. This paper also discusses the progress of clinical trials of icaritin. Icaritin was approved by the State Food and Drug Administration in January 2022 for the treatment of advanced HCC, and has various clinical drug prospects. Although it has some disadvantages, including poor solubility, and low bioavailability, icaritin is still a prospective candidate for the development of naturally derived drugs, especially in the treatment of tumors and inflammatory diseases. This review aims to update and deepen the understanding of icaritin, and provide a theoretical basis for its further study.

淫羊藿苷药理研究进展综述。
淫羊藿在中药中被广泛使用了几千年。这种植物以补肾阳,增强肌肉和骨骼,祛风祛湿而闻名。淫羊藿苷(icaritin)是一种从淫羊藿中分离得到的烯酰化类黄酮,近年来因其广泛的药理活性而受到越来越多的关注。淫羊藿苷在治疗多种疾病,如骨质疏松、肿瘤(肝癌、胃癌、乳腺癌和胶质母细胞瘤)、脑缺血皮肤损伤、血小板减少症和系统性红斑狼疮等方面显示出显著的治疗潜力。本文综述了淫羊藿苷的药理活性及其治疗相关疾病的潜在分子机制。数据提示,人畜藿苷可介导Wnt/[公式:见文]-catenin、IL-6/JAK2/STAT3、AMPK/mTOR、PTEN/AKT、MAPK、NF-[公式:见文]B等信号通路的药理作用。本文还讨论了淫羊藿苷的临床试验进展。淫羊藿苷于2022年1月获国家食品药品监督管理局批准用于晚期HCC的治疗,具有多种临床药物前景。尽管存在溶解度差、生物利用度低等缺点,但淫羊藿苷仍然是开发天然衍生药物的潜在候选药物,特别是在治疗肿瘤和炎症性疾病方面。本文旨在更新和加深对淫羊藿苷的认识,为其进一步研究提供理论依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信